Quick Answer
Profound Medical Corp. reported Cash and Equivalents of $59.72 million for fiscal year 2025.
Profound Medical Corp. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $59.72M | +8.8% |
| 2024 | $54.91M | +109.5% |
| 2023 | $26.21M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $24.83M | — | -29.5% |
| June 30, 2025 | $35.20M | — | -24.2% |
| March 31, 2025 | $46.43M | — | -15.4% |
| December 31, 2024 | $54.91M | — | — |
- Profound Medical Corp. showed an increase of +8.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Profound Medical Corp.’s cash and equivalents has grown by 127.8% (from $26.21 million to $59.72 million).
- The most recent figure is from Profound Medical Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: